Pill-and-urine cancer test under development at Carnegie Mellon

Category:

• Published:

Illustrative image: Owner-supplied News Now Georgia Atlanta edition logo. Branding graphic; not a scene, agency or incident photograph.

Carnegie Mellon University researchers are designing a cancer test that would combine an engineered pill with a urine sample, with a goal of screening for about 30 types of cancer. The technology remains in development and is not available to consumers.

Sensors in the pill are intended to seek tumors and release biological barcodes into urine if they find one. Researchers hope the sample could indicate cancer and potentially help identify its location. The target includes cancers that may be hard to detect early because symptoms can remain absent until the disease has advanced.

Researchers aim to begin human trials within four years and hope the technology could reach consumers within seven. Their longer-term vision is an annual at-home screening test that might cost as little as $100. Both the timeline and the price are future goals, not an available product or established market price.

Ellenwood resident Debra Kerney was diagnosed with stage 1 endometrial cancer in 2017 and is described as a two-time cancer survivor. She was diagnosed with stage 1 breast cancer in July, underwent surgery in August and is taking medication intended to reduce the risk of recurrence.

Marcus Jones
News Now Georgia

Share This Story